Publications

The references below are to peer-reviewed publications either related to the technology platforms of Caladrius Biosciences or authored/co-authored by Caladrius Biosciences.

T Regulatory Cell Technology

Bluestone, J., et al. (2015) Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Science Translational Medicine, 7 (315). http://stm.sciencemag.org/content/7/315/315ra189

Marek-Trzonkowsa, N., et al. (2014) Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets – results of one year follow-up. Clin Immunol.153(1):23-30. http://www.ncbi.nlm.nih.gov/pubmed/24704576 

Marek-Trzonkowska, N., et al. (2012.) Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care, 35(9): 1817-20. http://care.diabetesjournals.org/content/35/9/1817.long

Brunstein, C.G., et al. (2011.) Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood, 117(3): 1061-70. http://www.bloodjournal.org/content/117/3/1061.long?sso-checked=true

Hippen, K.L., et al. (2011.) Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with
minimal loss of in vivo functional activity. Sci Transl Med, 3(83): 83-83. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551476/

Tang, Q. and J.A. Bluestone, (2008.) The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol, 9(3): 239-44. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075612/

Tang, Q., et al. (2004.) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med, 199(11): 1455-65. http://jem.rupress.org/content/199/11/1455.long

 


CD34 Cell Technology

Arshed A Quyyumi, et al. (2016) PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients with Left Ventricular Dysfunction Post STEMI. Circulation Research, 119.10. http://circres.ahajournals.org/content/early/2016/11/07/CIRCRESAHA.115.308165

Assmus B, Leistner DM, Schächinger V, et al. (2014). Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. European heart journal, 35(19):1275-83. http://eurheartj.oxfordjournals.org/content/35/19/1275.long

Delewi, et al. (2014). Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. European heart journal, 35(15):989-98. http://eurheartj.oxfordjournals.org/content/35/15/989.long

Delewi, R., Andriessen, A., Tijssen, J. G. P., et al. (2012). Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a meta-analysis of randomized controlled clinical trials. Heart (British Cardiac Society). http://www.ncbi.nlm.nih.gov/pubmed/22875736

Zimmet, H., Porapakkham, P., Porapakkham, P., et al. (2012). Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. European journal of heart failure, 14(1), 91–105. http://onlinelibrary.wiley.com/doi/10.1093/eurjhf/hfr148/full

Schächinger, V., Erbs, S., Elsässer, A., et al. (2006). Improved clinical outcome after Intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. European heart journal, 27(23), 2775–83. http://eurheartj.oxfordjournals.org/content/ehj/27/23/2775.full.pdf


Tumor Cell / Dendritic Cell Technology

Dillman, R.O., et al. (2015) Superiority in a Randomized Trial of Patient-Specific Dendritic Cell/Tumor Cell Vaccines Vs Tumor Cell Vaccines in Subsets Defined by Disease Stage, Tumor Measurability, and Lactate Dehydrogenase (LDH) Level. Poster presented at: Society for Melanoma Research 2015 Congress; November 2015. San Francisco, CA. http://clbs.bio/1OhEf7q

Nistor, G., et al. (2015) Mechanism of Action of CLBS20: A Patient-Specific Immunotherapy Targeting Metastatic Melanoma. Poster presented at: Society for Melanoma Research 2015 Congress; November 2015. San Francisco, CA. http://clbs.bio/1OhEf7q

Dillman, R.O., et al. (2015) Superiority of Dendritic Cell Vaccine Vs Tumor Cell Vaccine: Survival by Stratification Subsets in MACVAC Randomized Phase II Trial of Patient-Specific Vaccines Utilizing Antigens from Autologous Melanoma Tumor Cell Lines. Poster presented at: The Society for Immunotherapy of Cancer 30th Anniversary Annual Meeting & Associated Programs; November 2015; National Harbor, MD. http://clbs.bio/1lwITFe

Nistor, G., et al. (2015) Functional Properties of Patient-Derived Melanoma Cancer Stem Cells. Poster presented at: The Society for Immunotherapy of Cancer 30th Anniversary Annual Meeting & Associated Programs; November 2015; National Harbor, MD. http://clbs.bio/1HZtyqw

Dillman, R.O., et al. (2015) Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. Cancer biotherapy and radiopharmaceuticals, doi: 10.1089/cbr.2015.1843. http://online.liebertpub.com/doi/pdfplus/10.1089/cbr.2015.1843

Dillman, R.O., et al. (2015.) Cancer Vaccines: Can They Improve Survival? Cancer biotherapy and radiopharmaceuticals, doi:10.1089/cbr.2014.1805. http://online.liebertpub.com/doi/full/10.1089/cbr.2014.1805

Dillman, R.O. (2015.) Patient-specific therapeutic vaccines for metastatic melanoma. Oncology issues, March/April 48-57. http://www.nxtbook.com/nxtbooks/accc/oncologyissues_20150304/index.php?startid=48

Bayer, M., et al. (2014.) Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B positive patients with hepatocellular carcinoma. J surg oncol doi: 10.1002/jso.23897 http://onlinelibrary.wiley.com/doi/10.1002/jso.23897/full

Dillman, R.O., A.N. Cornforth, and C. DePriest. (2013.) Cancer Stem Cell Antigens from Autologous Tumor Cell Lines in Patient-Specific Active Immunotherapy for Metastatic Cancer, Stem Cell and Cancer Stem Cells, Volume 9, 271-84. http://link.springer.com/chapter/10.1007%2F978-94-007-5645-8_26

Dillman, R.O., A.N. Cornforth, and G. Nistor. (2013.) Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma? Expert opin biol ther, 13(5): 643-56. http://www.ncbi.nlm.nih.gov/pubmed/23451922

Dillman, R.O., et al. (2012.) Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J immunother, 35(8): 641-49. http://www.ncbi.nlm.nih.gov/pubmed/22996370

Dillman, R.O., et al. (2010.) Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer biother radiopharm, 2010. 25(5): 553-57. http://online.liebertpub.com/doi/pdf/10.1089/cbr.2010.0819

Dillman R.O., (2009.) Whole tumor cell vaccine therapy in the treatment of patients with NSCLC. Symposium on Immunotherapy for the Treatment of Non-Small Cell Lung Cancer, 13th Annual International Lung Cancer Congress.

Dillman, R.O., et al. (2009.) Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer biother radiopharm, 24(3): 311-19. http://online.liebertpub.com/doi/pdf/10.1089/cbr.2008.0599

Dillman, R.O., S.K. Nayak, and L. Beutel. (1993.) Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. Journal of immunotherapy, 14(1): 65-69. http://journals.lww.com/immunotherapy-journal/Abstract/1993/07000/Establishing_In_Vitro_Cultures_of_Autologous_Tumor.9.aspx


Commentary

Preti, Robert (2015). Guest Commentary: Building a Problem or a Solution? Drug Discovery News. http://ddn-news.com/news?newsarticle=9878

Sietsema W, Wekselman K. (2015.) Agency Meetings with the US Food and Drug Administration. Regulatory Focus. Regulatory Affairs Professionals Society. http://www.raps.org/Regulatory-Focus/Features/2015/06/09/22643/Agency-Meetings-with-the-US-Food-and-Drug-Administration/